ERBB2 and breast carcinoma: Similar to aggressive breast cancers overexpressing the human epidermal growth factor receptor-2 (HER2); a proportion of GE cancers overexpress HER2 and have been approved for the use of HER2-targeting therapies in patients [14,15,16].